Stockscreener 앱 받기
17.15
4.99%
-0.90
시간 외 거래:
17.27
0.12
+0.70%
Forte Biosciences Inc 주식(FBRX)의 최신 뉴스
One Forte Biosciences Insider Raised Stake By 30% In Previous Year - Yahoo Finance
[EFFECT] Forte Biosciences, Inc. SEC Filing - Stock Titan
FBRX Q1 2026 Earnings: Wider-than-Expected Loss as Biotech Continues DevelopmentMargin Guidance - newsline.com
Trading Systems Reacting to (FBRX) Volatility - Stock Traders Daily
Millennium Group (FBRX) reports shared control of 1,062,182 shares - Stock Titan
Forte Biosciences (FBRX) Edges Lower Amid Sector Volatility, Key Support HoldsSmart Money Flow Stocks - newsline.com
Number of shareholders of Forte Biosciences Inc. – GETTEX:37T - TradingView
Forte Biosciences (FBRX) Slips 1% as Stock Consolidates Between Key Support and ResistanceTrend Continuation Trade - newsline.com
Forte Biosciences (NASDAQ: FBRX) files $500M shelf to sell securities - Stock Titan
Forte Biosciences Shareholders Approve Directors and Governance Items - TipRanks
Forte Biosciences (NASDAQ: FBRX) director receives 18,353 RSU equity award - Stock Titan
Forte Biosciences (NASDAQ: FBRX) files $500M shelf; highlights FB102 clinical wins - Stock Titan
Forte Biosciences (FBRX) director awarded 18,353 restricted stock units in equity grant - Stock Titan
Forte Biosciences (FBRX) director granted 18,353 RSUs in equity award - Stock Titan
Forte Biosciences (FBRX) director awarded 18,353 RSUs vesting after 2026 meeting - Stock Titan
Director at Forte Biosciences (NASDAQ: FBRX) awarded 18,353 RSUs as equity grant - Stock Titan
Forte Biosciences (FBRX) awards 18,353 RSUs to director Steven Kornfeld - Stock Titan
Forte Biosciences (FBRX) stockholders approve amended 2021 equity incentive plan - Stock Titan
Insider Buyers Lose Additional US$69k As Forte Biosciences Dips To US$466m - Moomoo
FBRX Q1 2026 Earnings: EPS Misses Estimates as Pre-Revenue Biotech Continues Clinical Progress - newsline.com
Forte Biosciences (FBRX) price target increased by 19.72% to 65.02 - MSN
Forte Biosciences Slides As Insider Purchases Lose Another US$70k - simplywall.st
Forte Biosciences (FBRX) Tumbles 8% as Bears Test Support at $18.12Insider Buying Alerts - newsline.com
Forte Biosciences Inc stock (US34960P1012): shares slip after recent Q1 loss and high volatility - AD HOC NEWS
FBRX - Finviz
FBRX Q1 2026 Earnings: Pre-Revenue Biotech Reports Narrow EPS Miss Amid Ongoing DevelopmentSurprise Factor Analysis - newsline.com
Forte Biosciences Q1 2026 Earnings: Pre-revenue Biotech Misses EPS Estimates; Stock Dips on Narrower Loss MissTech Earnings Analysis - The Legal Advocate
FBRX Q1 2026 Earnings: Wider-than-Expected Loss Reflects Pre-Revenue Biotech RealityLive Trade Sharing - Newser
Forte Biosciences stock (US34960P1012): Q1 update keeps focus on skin disease pipeline - AD HOC NEWS
(FBRX) and the Role of Price-Sensitive Allocations - Stock Traders Daily
Forte Biosciences Inc stock (US34960P1012): clinical pivot and cash focus keep biotech investors ale - AD HOC NEWS
Forte Biosciences stock (US34960P1012): volatile biotech after recent sell-off tests investor nerves - AD HOC NEWS
Forte Biosciences stock (US34960P1012): New 13G filings highlight major holders - AD HOC NEWS
Forte Biosciences Stock: Targeting Celiac Disease (NASDAQ:FBRX) - Seeking Alpha
OrbiMed entities hold 5.8% of Forte Biosciences (FBRX), ownership split disclosed - Stock Titan
Point72 entities report 0% ownership in Forte Biosciences (FBRX) - Stock Titan
MPM BioImpact LLC takes a 7.2% position in Forte Biosciences (NASDAQ: FBRX) - Stock Titan
Alger Associates (NASDAQ: FBRX) reports 1.27M shares; 10.2% stake - Stock Titan
Janus Henderson (FBRX) discloses 9.99% holding; 299,798 pre-funded warrants - Stock Titan
Forte Biosciences (NASDAQ: FBRX) deepens Q1 loss while FB102 wins Fast Track - Stock Titan
Affinity Asset Advisors takes 7.3% stake in Forte Biosciences (NASDAQ: FBRX) - Stock Titan
Forte Biosciences stock (US34960P1012): Q1 2026 earnings report upcoming - AD HOC NEWS
Forte Biosciences Inc reports results for the quarter ended March 31Earnings Summary - TradingView
Adage (FBRX) files Schedule 13G reporting 950,000-share stake - Stock Titan
Forte Biosciences stock (US34960P1012): Q1 2026 results and FDA Fast Track for FB102 - AD HOC NEWS
Chardan Capital Maintains Forte Biosciences(FBRX.US) With Buy Rating, Maintains Target Price $61 - Moomoo
MSN Money - MSN
TD Cowen Maintains Forte Biosciences(FBRX.US) With Buy Rating - Moomoo
Forte Biosciences Grants 66,667 RSUs to New Employee as Inducement - geneonline.com
New Forte Biosciences hire gets 50K options, 50K RSUs to join - Stock Titan
Forte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing Rules - The Joplin Globe
Forte Biosciences Releases Q1 2026 Financial Results - AlphaStreet
TradingKey - TradingKey
Forte Biosciences, Inc. 1Q 2026: Net loss $(22.1M), Diluted EPS $(1.24) — 10-Q Summary - TradingView
1.27%
1.43%
자본화:
|
볼륨(24시간):